ArticleBMC medicine2026
Kinetics of antibodies and risk of respiratory syncytial virus infection: a longitudinal cohort in Taizhou City, eastern China.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) causes recurrent infections throughout life. Yet, the form and durability of antibody-mediated protection induced by infection remained poorly understood.
methodsWe conducted a longitudinal cohort study in Taizhou City, China. Participant age distribution approximately reflected the age structure of population in Taizhou. Blood samples were collected at baseline (March 12, 2023) and four follow-up visits (May 7-26, 2023, August 13-23, 2023, November 12, 2023, and June 2-3, 2024). Serum-specific RSV pre-fusion F (PreF) protein antibody titres were measured for all samples, and neutralising antibodies against RSV strain A2 and RSV strain B were assessed in a subset. Using a Bayesian inference framework and reversible-jump Markov Chain Monte Carlo, we recovered individual infection histories, estimated population-level RSV incidence, and characterised antibody dynamics from longitudinal PreF titres. We also estimated the correlates of protection (COP) by quantifying the relationship between PreF antibody titres and infection risk.
resultsA total of 508 individuals were included. Over the study period, two RSV epidemic waves were observed: the first wave between May and November 2023 and the second from February to May 2024. We estimated seasonal RSV infection rates of 4-7% in the community-based population. Post-infection immunity responses were most robust in young children ≤ 5 years and weakest in adults ≥ 75 years, with peak fold rises in antibody titres of 29.4 and 5.4, respectively. The post-infection antibody titres declined substantially, with fourfold rises sustained for an average of 128 days (95% credible interval of 21-281). The probability of protection given exposure increased with higher PreF titres across all age groups. However, the predictive performance of PreF titres as a COP varied markedly by age: titres strongly predicted protection in young children but showed weaker discrimination in older children and adults, and minimal predictive value in the oldest adults.
conclusionsThese results revealed age-related differences in the durability and protective value of natural infection-elicited RSV PreF antibody responses, emphasising the importance of age-specific prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.